Carnegie Mellon University •
March 1, 2021
Scalable manufacturing for novel, painless vaccine delivery
Collaborators led by Carnegie Mellon University are developing a novel approach to COVID-19 inoculation that addresses both immunological effectiveness and manufacturing efficiency with a low-dose, inexpensive, hybrid microneedle array (Hybrid-MNA) technology.